Strumento inattivo

Altre lingue Santhera Pharmaceuticals Holding AG Xetra

Azioni

S3F

CH0027148649

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Santhera Publishes Agenda for its Annual General Meeting	28/05
Santhera Publishes Annual Report 2023	28/05
Santhera dans les chiffres noirs en 2023	25/04
Santhera Pharmaceuticals Swings to Profit in FY23; Revenue Grows	25/04
Santhera dank Catalyst-Deal mit gutem Finanzpuffer - ab 2026 Break-Even geplant	25/04
Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May	25/04
Santhera Pharmaceuticals Holding AG Reports Earnings Results for the Full Year Ended December 31, 2023	25/04
Santhera Pharmaceuticals Holding AG Reports Earnings Results for the Full Year Ended December 31, 2023	25/04
Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis	17/04
Spexis: sursis concordataire prolongé de 4 mois après réception d'un paiement	17/04
Santhera obtient un statut d'examen prioritaire en Chine pour le vamorolone	27/03
Santhera Pharmaceuticals Wins Priority Review for Duchenne Muscular Dystrophy Drug in China	27/03
Santhera kommt mit möglicher Zulassung von Vamorolon in China entscheidend voran	27/03
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China’s NMPA	27/03
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Grants Priority Review by China's NMPA	27/03
Santhera-Partner Catalyst Pharmaceuticals lanciert Agamree in den USA	14/03
Santhera: lancement de l'Agamree contre la myopathie de Duchenne aux USA	14/03
Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States	14/03
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical?s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology	21/02
Aktien Schweiz auf Erholungskurs	14/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Santhera Pharmaceuticals Holding AG Xetra

Azioni

S3F

CH0027148649

Altre lingue

Filtri